Loading
NASDAQHealthcareMedical - Devices
Latest quote
$0.5426
+$0.0626 · +13.04%
InspireMD, Inc., an Israel-based medical technology company established in 2005, specializes in creating and commercializing advanced medical devices. Its core expertise lies in the proprietary MicroNet stent platform technology, engineered to address various vascular and coronary diseases. The company's offerings, distributed through a network of local partners, reach markets across Europe, Latin America, the Middle East, and Asia Pacific. Key products include the CGuard carotid embolic prevention system, specifically designed for carotid artery procedures, and the MGuard Prime embolic protection systems. The MGuard Prime systems are crucial for patients experiencing acute coronary syndromes, notably acute myocardial infarction, and those undergoing saphenous vein graft coronary interventions or bypass surgery. InspireMD is also developing PVGuard, an innovative solution combining a MicroNet mesh sleeve with a self-expandable stent, aimed at peripheral vascular applications.
Regular session
$0.5426
+$0.0626 · +13.04%
Regular session · ET · Market data may be delayed.
InspireMD, Inc., an Israel-based medical technology company established in 2005, specializes in creating and commercializing advanced medical devices. Its core expertise lies in the proprietary MicroNet stent platform technology, engineered to address various vascular and coronary diseases. The company's offerings, distributed through a network of local partners, reach markets across Europe, Latin America, the Middle East, and Asia Pacific. Key products include the CGuard carotid embolic prevention system, specifically designed for carotid artery procedures, and the MGuard Prime embolic protection systems. The MGuard Prime systems are crucial for patients experiencing acute coronary syndromes, notably acute myocardial infarction, and those undergoing saphenous vein graft coronary interventions or bypass surgery. InspireMD is also developing PVGuard, an innovative solution combining a MicroNet mesh sleeve with a self-expandable stent, aimed at peripheral vascular applications.
Day range
Current $0.5426
52-week range
Current $0.5426
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
67
Undervalued
Sentiment
68
Bullish
Risk
69
High Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
InspireMD, Inc., an Israel-based medical technology company established in 2005, specializes in creating and commercializing advanced medical devices. Its core expertise lies in the proprietary MicroNet stent platform technology, engineered to address various vascular and coronary diseases. The company's offerings, distributed through a network of local partners, reach markets across Europe, Latin America, the Middle East, and Asia Pacific. Key products include the CGuard carotid embolic prevention system, specifically designed for carotid artery procedures, and the MGuard Prime embolic protection systems. The MGuard Prime systems are crucial for patients experiencing acute coronary syndromes, notably acute myocardial infarction, and those undergoing saphenous vein graft coronary interventions or bypass surgery. InspireMD is also developing PVGuard, an innovative solution combining a MicroNet mesh sleeve with a self-expandable stent, aimed at peripheral vascular applications.
Day range
Current $0.5426
52-week range
Current $0.5426
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 8.98M USD | 7.01M USD | 6.21M USD | 5.17M USD | 4.5M USD |
| Cost of goods sold | 6.33M USD | 5.5M USD | 4.4M USD | 4.05M USD | 3.74M USD |
| Gross profit | 2.65M USD | 1.51M USD | 1.81M USD | 1.12M USD | 754K USD |
| Research and development | 15M USD | 13.63M USD | 7.98M USD | 7.81M USD | 5.16M USD |
| Selling, general, and administrative | 37.26M USD | 21.38M USD | 14.97M USD | 12.02M USD | 10.31M USD |
| Operating expenses | 51.76M USD | 35.01M USD | 22.95M USD | 19.83M USD | 15.47M USD |
| Interest income | — | 1.56M USD | 1.29M USD | 250K USD | — |
| Interest expense | — | — | — | — | 157K USD |
| Depreciation and amortization | 476K USD | 280K USD | 232K USD | 188K USD | 161K USD |
| Operating income | −49.11M USD | −33.5M USD | −21.14M USD | −18.71M USD | −14.72M USD |
| Net income | −48.79M USD | −32.01M USD | −19.92M USD | −18.49M USD | −14.92M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$3.50
545.04% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Apr 27, 2021 | 1:15 | — | — |
Stock split | Apr 1, 2019 | 1:50 | — | — |
Stock split | Feb 8, 2018 | 1:35 | — | — |
Stock split | Oct 10, 2016 | 1:25 | — | — |
Stock split | Oct 1, 2015 | 1:10 | — | — |
Stock split | Dec 21, 2012 | 1:4 | — | — |
Effective Apr 27, 2021
1:15
Effective Apr 1, 2019
1:50
Effective Feb 8, 2018
1:35
Effective Oct 10, 2016
1:25
Effective Oct 1, 2015
1:10
Effective Dec 21, 2012
1:4
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
